Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
-
New eye injection safety tested for Age-Related vision loss
Disease control CompletedThis study tested the safety of pegcetacoplan eye injections delivered via a prefilled syringe for people with geographic atrophy, a form of age-related macular degeneration that causes progressive vision loss. It involved 44 participants aged 60 and older who were already candid…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 04, 2026 05:05 UTC
-
Three-Year eye injection study aims to protect vision in aging eyes
Disease control CompletedThis study followed nearly 800 people for up to three years to see if regular injections of the drug pegcetacoplan into the eye are safe and effective for the long term. The goal was to slow the progression of geographic atrophy, a form of age-related macular degeneration that ca…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Breakthrough injection shows promise for devastating kidney conditions
Disease control CompletedThis Phase 3 study tested whether pegcetacoplan injections could help people with rare kidney diseases called C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The trial involved 124 participants who received either the actual drug or p…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC